Karen Ortiz Cruz, MD
Hematology & Oncology · Chandler, AZNPI 1912168535
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $17,475 of the $25,807 with a category attached, or 67.7%. It is spread thinly across 60 manufacturers, the largest accounting for just 19.7%. 2025 is the largest year on record at $9,189, 5.1 times the $1,804 reported in 2019.
Across 986 payments — averaging $26.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stemline Therapeutics Inc.$5K
- Novartis$2K
- Daiichi Sankyo Inc.$2K
- AstraZeneca$1K
- Bristol Myers Squibb$1K
- Pfizer$1K
- plus $13K from 54 others
Across 2 payments — averaging $106,019 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$212K
What the payments were for
- Consulting fees$6,42525%
- Food & beverage$17,47568%
- Education$7553%
- Entertainment$210%
- Other$1,1314%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Orserdu$4,960
- Indigo System$513
- Assure WCD$381
- Impella$266
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$162
- KISQALI$119
- KEYTRUDA$100
How this compares
$25,807 in reported general payments places this provider in the 75th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 48 | $839,916 |
| KisqaliRibociclib Succinate | 36 | $610,125 |
| ImbruvicaIbrutinib | 34 | $519,345 |
| Lenalidomide | 23 | $365,964 |
| RetevmoSelpercatinib | 13 | $279,399 |
| RevlimidLenalidomide | 15 | $267,427 |
| XtandiEnzalutamide | 24 | $259,173 |
| MektoviBinimetinib | 12 | $189,241 |
| NinlaroIxazomib Citrate | 13 | $164,612 |
| EliquisApixaban | 140 | $92,541 |
| Abiraterone Acetate | 20 | $62,195 |
| XareltoRivaroxaban | 40 | $40,581 |
| Anastrozole | 707 | $15,044 |
| Exemestane | 72 | $10,211 |
| Letrozole | 114 | $3,405 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $269 | $839,91648 claims |
| NovartisKisqali | $2,492 | $610,12536 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $528 | $519,34534 claims |
| Lilly USA, LLCRetevmo, Olanzapine | $196 | $280,05741 claims |
| Bristol Myers SquibbRevlimid | $1,130 | $267,42715 claims |
| Astellas Pharma US IncXtandi | $507 | $259,17324 claims |
| Array Biopharma IncMektovi | $265 | $189,24112 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $428 | $164,61213 claims |
| PfizerEliquis | $1,128 | $92,541140 claims |
| Johnson & JohnsonXarelto | $1,054 | $40,58140 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 261 hematology & oncology providers in Arizona.
Other hematology & oncology in Chandler
- Sujith KalmadiChandler$1.4M
- Mikhail ShtivelbandChandler$42K
- Rohit SudChandler$34K
- Arun SingaviChandler$26K
- Jeffrey SchriberScottsdale$715K
- Javier MunozPhoenix$638K
- Tanios Bekaii-SaabScottsdale$527K
- Rajesh KukunoorScottsdale$499K
- Sumit MadanGilbert$422K
- Christopher ChenTucson$370K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.